Extended Data Fig. 3: Baseline Characteristics. | Nature Medicine

Extended Data Fig. 3: Baseline Characteristics.

From: Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial

Extended Data Fig. 3: Baseline Characteristics.

Baseline characteristics including for patients not included in the interim analysis (n = 30). AdvSM, advanced systemic mastocytosis; ASM, aggressive systemic mastocytosis; ddPCR, droplet digital polymerase chain reaction; ECOG, Eastern Cooperative Oncology Group; MCL, mast cell leukemia; mIWG-MRT-ECNM, modified International Working Group-Myeloproliferative Neoplasms Research and Treatment and European Competence Network on Mastocytosis; SM-AHN, systemic mastocytosis with associated hematologic neoplasm.

Back to article page